Fairmount Funds Management LLC, Director at Zenas BioPharma, Inc. (ZBIO), bought 150,000 shares at $20.00 ($3.0M) on 2026-03-31, disclosed to the SEC on 2026-04-01.
Open-market purchase of $3.0M ZBIO by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| SYRE | SELL | 2026-06-23 | $399.7M | — | Filing → |
| VRDN | BUY | 2026-05-13 | $20.0M | — | Filing → |
| COGT | SELL | 2026-03-31 | $242.6M | — | Filing → |